NeuPulse

Executive Summary

NeuPulse is a UK-based medical device company developing a non-invasive, wearable wrist device for the on-demand treatment of Tourette Syndrome. The device delivers targeted median nerve stimulation to reduce the frequency and severity of tics, offering a drug-free alternative to existing therapies. Founded in 2020 and headquartered in London, the company is privately held and has not disclosed funding details. Its approach leverages neuromodulation to integrate into daily life, potentially addressing a significant unmet need in the Tourette Syndrome market, which lacks effective non-pharmacological options. The company is likely advancing through clinical validation and regulatory pathways. Given its UK base, near-term milestones may include CE marking for European commercialization and early-stage US clinical trials. NeuPulse operates in the growing neuromodulation space, estimated at over $6 billion by 2026, and Tourette Syndrome affects approximately 1% of the population globally. With a novel, non-invasive approach and a clear patient need, NeuPulse is positioned for potential growth, though it remains early-stage with no disclosed revenues or partnerships.

Upcoming Catalysts (preview)

• Q1 2026CE Mark Approval for European Market70% success
• Q4 2026Initiation of US Pivotal Trial60% success
• Q3 2025Publication of Pilot Study Results80% success